Butyrate-loaded bacterial extracellular vesicles for healthy weight management in pets

Overview

BioClé has developed a cell-free delivery platform that uses bacterial extracellular vesicles (bEVs) produced from GRAS bacteria to transport butyrate, a microbiome-derived metabolite with established roles in intestinal barrier function, metabolic regulation, fatty acid oxidation, and gut-mediated satiety pathways, including GLP-1 and PYY signaling. The platform is designed to protect butyrate from degradation during digestion, delivering it intact to intestinal cells where it can exert its metabolic effects.

The ingredient is formulated to be incorporated directly into treats, wet food, or dry food for dogs and cats, allowing pet owners to add the functional benefit without replacing the animal's regular diet. By improving delivery efficiency, the technology aims to achieve efficacy at a lower effective dose compared with free butyrate, creating a practical and cost-effective approach to weight management in pets.

Technical specifications

Key features:

• Butyrate-loaded vesicles produced from a GRAS bacterial chassis, ensuring a cell-free, naturally derived product with a credible regulatory path
• Demonstrated high particle yields and compatibility with lyophilization, supporting scalable production and ambient storage formats
• Early in vivo studies in C. elegans show more than twice the biological effect of free butyrate and a reduction in fat accumulation of over 40%
• Designed for incorporation into treats, wet food, and dry food; thermal retention testing at 100–140 °C is planned, with post-process application or protective coatings evaluated as needed

The development plan includes optimizing butyrate loading and formulation, assessing vesicle integrity, cargo retention, and biological activity under relevant temperature, moisture, and storage conditions, and confirming cellular uptake, cytotoxicity, and effects on metabolic and satiety pathways through in vitro assays.

Technology readiness level

The platform is currently at an early validation stage. The delivery advantage has been demonstrated in vitro and in a C. elegans model, but pet-specific efficacy, palatability, and gastrointestinal tolerance have not yet been established. A stage-gated plan is proposed: define the target product profile for treats, wet food, and dry food; optimize formulation and validate stability; conduct in vitro metabolic and satiety assays; run dose-ranging and palatability studies in dogs and cats; and complete a controlled feeding study comparing the product with free butyrate and placebo, measuring food intake, body weight, body fat, lean mass, body condition, activity, GLP-1, PYY, and metabolic markers.